Drug Trial Radar · NCT07088263
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Sep 15, 2025
Primary completion
Jul 24, 2027
Study completion Jun 24, 2028
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of advanced breast cancer progressive after standard treatment.
Conditions
- Breast Neoplasms
Interventions
Gemcitabine, Vinorelbine, Eribulin, or UtideloneDrug
Gemcitabine, Vinorelbine, Eribulin, or Utidelone is recieved every 28 days. The chemotherapy interval is one cycle every 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival (PFS)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.